AzTrials
AzTrials

Lung CancerNCT01975623

Pulmonary Artery Sealing Using the HARMONIC ACE+ Shears(HS) for VATS Lobectomy

A study testing HARMONIC ACE®+ Shears (HS) in people with Lung Cancer, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

VATS anatomical lung resection provides an effective minimally invasive treatment strategy for stage I and II lung cancer. VATS lobectomy is associated with significantly less postoperative atrial fibrillation, blood transfusion, renal failure, and other complications when compared with lobectomy via thoracotomy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Lung Cancer
What is being tested?
HARMONIC ACE®+ Shears (HS)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
47 participants
Where
1 siteCanada
Study dates
Sep 2013to Apr 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • patients with non-hilar tumours undergoing anatomical pulmonary lung resection by either VATS or open thoracotomy,
  • patients undergoing lung explant prior to lung transplantation and
  • patients undergoing multiple visceral organ retrieval in which the lungs are not suitable for transplant.

Who cannot join

  • inability to consent (patient or family member in case of recipient organ),
  • patient < 18 years old,
  • patients with hilar tumours in proximity to major PAs that might affect the integrity of the pathological vascular margin.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2L 4M1

Other trials in Canada

About this study

Official title: Ex-Vivo Evaluation of the Effectiveness of Pulmonary Artery Sealing Using the HARMONIC ACE + Shears (HS) for VATS Lobectomy

VATS anatomical lung resection provides an effective minimally invasive treatment strategy for stage I and II lung cancer. VATS lobectomy is associated with significantly less postoperative atrial fibrillation, blood transfusion, renal failure, and other complications when compared with lobectomy via thoracotomy.

Although VATS lobectomy has been proven to be effective and safe in experienced hands, it is not devoid of risk. Intra-operative surgical complications can be at times catastrophic.

Currently, in spite of being a safe and effective technique in experienced hands, a minority of anatomical pulmonary resections are being performed by VATS. The technical difficulty and increased actual and perceived danger of VATS lobectomy is related to PA branch manipulation and this is the main limitation for many thoracic surgeons regarding the adoption of VATS lobectomy into their practise. Furthermore, the majority of VATS lobectomies are being performed in high volume, academic medical centers with a resultant disparity in socioeconomic status between those that undergo VATS versus open lobectomy. If we can find a way to decrease the manipulation required by the surgeon on the PA branches, these procedures will be safer, less stressful for the surgeon and therefore more prevalent for anatomical pulmonary resections.

Read the detailed description

The intraoperative techniques will not differ from standard resection techniques and blood vessel ligation will be performed according to standard operative procedures either using endostaplers or direct ligation of the pulmonary vessels.

After resection and removal of the resected specimen, the specimen will be examined ex-vivo, out of the operative field in a non-sterile field in the operative room. The lobar PA and its main segmental branches will be sharply dissected. Cannulation of a major segmental PA branch will be performed using our pressurization and monitoring device. The cannulation will be secured with a 2-0 silk suture. The vascular pressurization and recording device has been described in section E and is outlined in Figures 4 and 5. All pressure measurements will be recorded and graphed related to time from initial vascular pressurization to PA bursting pressure.

All distal segmental branches of the PA will be ligated to maintain the pressure throughout the catheterized segmental branch. An initial pressure of 25 mmHg will be obtained by inflating the vessel with normal saline. The lobar PA and the main segmental branches' diameters will be measured from vascular adventitia to adventitia. The lobar PA and the main segmental arteries will be sealed using the Harmonic Scalpel Ace+. The sealing will be performed with an intravascular pressure of 25 mmHg in order to simulate normal human PA pressures.

Following division of the PA, normal saline solution will be injected through the controlled pressure syringe pump in order to achieve an intralumenal vascular pressure until the bursting pressure is reached. Intralumenal pressure will be recorded at a frequency of 10 times per second. The bursting pressure will be recorded. Ex-vivo experimentation will take approximately 20 to 30 minutes. Burst pressure of the in-vivo endo-stapled (Endopath® ETS, 35mm, 2.5mm staples, white cartridge; Ethicon, Cincinnati, Ohio, USA) main lobar PA branches will be evaluated and recorded ex-vivo on the same specimens.

Endo-stapled vessels will be utilized as the size-matched control for energy sealed vessels in a 1:2 ratio. Allotment into the stapled or energy sealed group will be based on vascular size measurement prior to sealing. Attempts will be made to use the in-vivo staple line as the control vessel in all possible cases (size permitting) in order to increase the sample size of the energy sealed vessels.

Following vascular sealing, experimentation and recordings, the specimen will be sent for pathological evaluation of the resected lesion. All specimen manipulations will be strictly performed on the proximal main PA branches, away from the resected tumour. Care will be taken to not affect the pathological integrity of the resected lesion and its surrounding tissue and lymph nodes. Experimentation will be performed under the direct supervision of the attending thoracic surgeon in order to assure integrity of the specimen for pathological analysis.

Analysis will consist of between group comparisons of the efficacies and bursting pressure of both the energy sealed vessels (experimental group) and the endostapler-sealed vessels (control group). Vessels will be stratified by luminal diameter by millimeter. Primary outcome for analysis will be the intergroup comparisons of mean PA burst pressure by size of vessel. Intergroup differences will be compared with the student's t-test with bursting pressures entered as a continuous variable. Statistical testing for normality of data will be performed and when data is non-normal, non-parametric methods (ex: Wilcoxon Rank Sum Test…) will be used. Multivariable linear regression models will be employed in order to compare burst pressures between groups controlling for potential confounders (disease state, size of vessel sealed, age of patient, sex, pulmonary lobe, laterality, immunosupression, diabetes, vascular disease…).

Conditions
Lung Cancer
Being tested
HARMONIC ACE®+ Shears (HS)
Keywords
Video assisted thoracoscopic surgery (VATS)
Medical subject headings
Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HARMONIC ACE®+ Shears (HS)Device

    We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).

Study groups in NCT01975623
Study groupRoleWhat they receive
Intervention GroupExperimentalPulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
Receives: Device: HARMONIC ACE®+ Shears (HS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary outcome for analysis will be the intergroupe comparison of mean PA burst pressures.

    Intergroup differences will be compared with the student's t-test with bursting pressures entered as a continuous variable. Statistical testing for normality of data will be performed and when data is non-normal, non-parametric methods (ex: Wilcoxon Rank Sum Test…) will be used. Multivariable linear regression models will be employed in order to compare burst pressures between groups controlling for potential confounders (disease state, size of vessel sealed, age of patient, sex, pulmonary lobe, laterality, immunosupression, diabetes, vascular disease…).

    Measured: 5 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Nov 2013 (estimated)
  2. Study startSep 2013
  3. Primary completionDec 2014
  4. Study completionApr 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
47 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01975623
Sponsor's protocol ID
12.262
Status last verified
May 2015
First submitted
29 Oct 2013
Last updated
26 Nov 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing HARMONIC ACE®+ Shears (HS) in people with Lung Cancer, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary outcome for analysis will be the intergroupe comparison of mean PA burst pressures. (time frame: 5 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in